The PD‐1/PD‐L1 immune checkpoint blockade therapy aims to restore T cell‐mediated tumor immunity by blocking PD‐1/PD‐L1 signaling; however, F. nucleatum counteracts this in multiple cancers. This evidence concerns the gene CD274 and cancer.